[Skip to Content]
[Skip to Content Landing]
Invited Commentary
June 2014

Role of Sildenafil in Melanoma Incidence and Mortality

Author Affiliations
  • 1Editor, JAMA Dermatology
  • 2Department of Dermatology, Northwestern University Feinberg School of Medicine, Chicago, Illinois
JAMA Intern Med. 2014;174(6):970-971. doi:10.1001/jamainternmed.2014.157

In 2014, about 76 100 new melanomas will be diagnosed, and an estimated 9710 persons will die (about 6470 men and 3240 women).1 Patients with melanoma in situ, stage 0, have a 5-year survival rate of 99% when treated with excision, whereas those with melanoma limited to the skin and with a tumor thickness of 2.01 to 4.0 mm, stage II B, have a 5-year survival rate of about 57%. Patients with metastatic melanoma, stage IV, have a 5-year survival rate of 15% to 20%. Despite newly available targeted agents, systemic therapies rarely lead to cures. These sizable survival differences illustrate the need for early detection of melanoma; early detection of primary melanomas followed by surgical excision remains critical.

First Page Preview View Large
First page PDF preview
First page PDF preview
×